Press Release Revolution Medicines to Report Financial Results for Second Quarter 2026 After Market Close on August 5, 2026 Jul 29
Press Release Revolution Medicines’ New Drug Application for Daraxonrasib Accepted for Review by U.S. FDA for Previously Treated Metastatic Pancreatic Cancer Jul 22